Biotech company to showcase new instruments at ASAPS conference in Orlando April 21-24
April 11, 2006 — /MARKET WIRE/ — SAN DIEGO, Calif. — Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc. (OTC: CBSI), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today launched a new ecommerce site where it will merchandise its new disposable instruments and accessories for the surgical and hospital markets: www.tulipdisposable.com.
In addition, the company said it will showcase its new instruments and accessories at the American Society for Aesthetic Plastic Surgery (ASAPS) conference in Orlando, Florida from April 21-24, 2006. Demonstrations will take place in booth #611-613.
According to the company, production models of the company’s first disposable accessories, such as transfer devices, are available for sale now, while the company awaits final FDA clearance on its surgical cannulas.
Disposable instruments designed by Tulip BioMed use the patented SuperLuerLok(tm) technology to ensure stability and reliability while increasing safety for doctors and patients. There is no risk of cross-contamination from previous procedures because the products are disposable and never need to be re-sterilized. The company’s disposable cannulas are coated with a patent-pending lubricious coating that is designed to increase ease-of-use for the surgeon, as well as reduce patient trauma and aid in minimizing recovery time.
“We’re looking forward to the conference and being able to show the instruments to the physicians,” said President and COO Darin Andersen. “We have received an enthusiastic response from the surgeons who have seen the new instruments to date and we expect that our new ecommerce site will make it as easy for them to order the instruments as they are to use.”
About Tulip BioMed
Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc., (OTC: CBSI) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed is the exclusive licensee of patented syringe connection devices that use the worldwide-recognized Tulip brand name. Tulip BioMed manufactures, markets, and distributes medical devices adapted with these and other patented technologies to physicians, clinics, military, health organizations, hospitals and other distribution outlets. On the Web: http://www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.
Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, formerly Cell Bio-Systems, Inc. (“Cell Bio-Systems”), which is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “anticipate(s),” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Clearpoint Agency, Inc.
SOURCE: Cell Bio-Systems